Indication: Neuroblastoma
A Phase II Preventative Trial of DFMO as a Single Agent in Patients with High Risk Neuroblastoma in Remission (NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO))
Sub-indication: Neuroblastoma
Study Type: Drug Study
Principal Investigator: Ashok Raj, M.D.Norton Children's Cancer Institute, affiliated with the UofL School of Medicine
Sponsor: Sponsor: Beat Childhood Cancer
